Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)
NCT00048516 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 68
Last updated 2006-08-02
Summary
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
Conditions
- Renal Insufficiency, Chronic
Interventions
- DRUG
-
paricalcitol capsule
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Laura Williams, M.D. · Abbott
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-02-28
Countries
- United States
- Poland
Study Locations
More Related Trials
-
Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis
NCT01265992 ·Status: COMPLETED
-
Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience
NCT01083186 ·Status: COMPLETED
-
Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose
NCT00891813 ·Status: COMPLETED ·Phase: PHASE4
-
Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice
NCT01083849 ·Status: COMPLETED
-
Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years
NCT01073462 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
NCT00646035 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)
NCT01020487 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis
NCT00091481 ·Status: COMPLETED ·Phase: PHASE4
-
Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
NCT01273597 ·Status: COMPLETED
-
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
NCT00062699 ·Status: TERMINATED ·Phase: PHASE4
-
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
NCT01163162 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
NCT00421733 ·Status: COMPLETED ·Phase: PHASE2
-
Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism
NCT01081665 ·Status: COMPLETED
-
A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease
NCT00257920 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
NCT00977080 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
NCT01382212 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium
NCT00073710 ·Status: COMPLETED ·Phase: PHASE4
-
Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation
NCT01401478 ·Status: COMPLETED
-
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
NCT01071070 ·Status: COMPLETED ·Phase: PHASE3
-
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
NCT01191762 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
NCT01134315 ·Status: TERMINATED
-
Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation
NCT00428246 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
NCT01254565 ·Status: COMPLETED ·Phase: PHASE2
-
Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous
NCT01368042 ·Status: COMPLETED
-
A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism
NCT04994080 ·Status: UNKNOWN ·Phase: PHASE3